AGILeBiotics has been awarded a Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support the company will test its antibiotic candidates in a clinically relevant animal model of infection. The next goal is the nomination of an antibiotic candidate for pre-clinical development.
ZonMw (the Netherlands Organisation for Health Research and Development) is performing, on behalf of JPIAMR and the recently started consortium VALUE-Dx, a survey on resources (collections of biological material and databases) that are relevant for antimicrobial resistance (AMR) research. In parallel, they collect information about services that are provided by research infrastructures and some biobanks.
The Second Ministerial Conference on Antimicrobial Resistance (AMR) will take place in Grand Hotel Huis ter Duin, in the historic town of Noordwijk. Here, in this venue at sea, participant will explore what has been done since the first meeting that was organised five years ago, and to take further steps to accelerate the implementation of the Global Action Plan on AMR. For two days, working closely together with the World Health Organization (WHO), Food and Agriculture Organization (FAO) and World Organisation for Animal Health (OIE), participants will look back at recent global developments and explore new ways to work jointly to tackle the threat of antimicrobial resistance.
International organizations unite on critical recommendations to combat drug-resistant infections and prevent staggering number of deaths each year.
NADP Annual Meeting, 22 May 2019, Paushuize, Utrecht ‘Accelerating antibiotic development in Europe’
The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled ‘Accelerating antibiotic development in Europe’.
Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema.